Symbols / TXMD Stock $1.82 -2.15% TherapeuticsMD, Inc.

Healthcare • Drug Manufacturers - Specialty & Generic • United States • NMS
TXMD (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
CEO Mr. Marlan D. Walker J.D.
Exch · Country NMS · United States
Market Cap 21.07M
Enterprise Value 17.93M
Income 86.00K
Sales 3.35M
FCF (ttm) 1.33M
Book/sh 2.33
Cash/sh 0.73
Employees 1
Insider 10d —
IPO May 09, 2007
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E 182.00
Forward P/E 5.20
PEG —
P/S 6.28
P/B 0.78
P/C —
EV/EBITDA -12.75
EV/Sales 5.35
Quick Ratio 2.37
Current Ratio 3.11
Debt/Eq 17.89
LT Debt/Eq —
EPS (ttm) 0.01
EPS next Y 0.35
EPS Growth —
Revenue Growth 84.20%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2023-08-14
Earnings (prior) 2023-08-14
ROA -2.95%
ROE 0.32%
ROIC —
Gross Margin 100.00%
Oper. Margin -28.45%
Profit Margin 5.34%
Shs Outstand 11.57M
Shs Float 9.49M
Insider Own 7.45%
Instit Own 33.97%
Short Float 0.61%
Short Ratio 2.60
Short Interest 51.41K
52W High 2.95
vs 52W High -38.31%
52W Low 0.98
vs 52W Low 85.71%
Beta —
Impl. Vol. 0.53%
Rel Volume 1.83
Avg Volume 29.40K
Volume 53.71K
Target (mean) —
Tgt Median —
Tgt Low —
Tgt High —
# Analysts —
Recom None
Prev Close $1.86
Price $1.82
Change -2.15%
About

TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States and internationally. Its products portfolio includes IMVEXXY for the treatment of moderate-to-severe dyspareunia, a symptom of vulvar and vaginal atrophy due to menopause; BIJUVA to treat moderate-to-severe vasomotor symptoms due to menopause in women with a uterus; and ANNOVERA, a ring-shaped contraceptive vaginal system. The company also offers prescription prenatal vitamin products under the BocaGreenMD and vitaMedMD brand names. It has a license agreement with Mayne Pharma Group Limited. The company sells its products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$1.82
Latest analyst target
3. DCF / Fair value
$2.07
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.82
Low
—
High
—
Mean
—

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2023-08-17 reit Cantor Fitzgerald Neutral → Neutral $5
2022-07-13 reit Cantor Fitzgerald — → Neutral $1
2022-06-07 down HC Wainwright & Co. Buy → Neutral $10
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-12-23 THOMPSON TOMMY G Director — 8,400 $1.67 $14,031
2025-04-14 THOMPSON TOMMY G Director — 325 $1.00 $326
2025-04-14 WALKER MARLAN D Chief Executive Officer — 490 $1.00 $489
2025-04-10 WALKER MARLAN D Chief Executive Officer — 2,303 $0.86 $1,994
2025-02-18 THOMPSON TOMMY G Director — 8,500 — —
2025-02-18 COLLINS COOPER C Director — 8,500 — —
2025-02-18 WALKER MARLAN D Chief Executive Officer — 8,281 — —
2025-02-18 NAUGHTON GAIL K Director — 8,500 — —
2024-08-22 COLLINS COOPER C Director — 4,094 $1.73 $7,099
2024-08-21 COLLINS COOPER C Director — 1,200 $1.70 $2,039
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
3.02
+71.61%
1.76
+35.25%
1.30
-98.14%
69.96
Operating Revenue
3.02
+71.61%
1.76
+35.25%
1.30
-98.14%
69.96
Cost Of Revenue
—
—
0.00
-100.00%
1.40
Reconciled Cost Of Revenue
—
—
0.02
-98.42%
1.39
Gross Profit
—
—
1.30
-98.10%
68.57
Operating Expense
7.24
+9.55%
6.61
-32.77%
9.82
-83.03%
57.90
Research And Development
—
—
—
0.00
Selling General And Administration
6.85
+12.40%
6.10
-31.53%
8.90
-84.30%
56.71
Selling And Marketing Expense
—
—
—
0.00
General And Administrative Expense
6.85
+12.40%
6.10
—
57.90
Other Gand A
6.85
+12.40%
6.10
—
57.90
Total Expenses
7.24
+9.55%
6.61
-32.77%
9.82
-83.43%
59.30
Operating Income
-4.21
+13.01%
-4.84
+43.17%
-8.52
-179.93%
10.66
Total Operating Income As Reported
-4.39
+28.17%
-6.11
+28.29%
-8.52
-815.62%
1.19
EBITDA
-3.02
+15.24%
-3.56
+53.11%
-7.60
-164.07%
11.86
Normalized EBITDA
-2.85
-23.91%
-2.30
+69.79%
-7.60
-135.63%
21.34
Reconciled Depreciation
1.19
-6.80%
1.28
+38.83%
0.92
-23.17%
1.20
EBIT
-4.21
+13.01%
-4.84
+43.17%
-8.52
-179.93%
10.66
Total Unusual Items
-0.18
+86.12%
-1.27
0.00
+100.00%
-9.47
Total Unusual Items Excluding Goodwill
-0.18
+86.12%
-1.27
0.00
+100.00%
-9.47
Special Income Charges
-0.18
+86.12%
-1.27
0.00
+100.00%
-9.47
Impairment Of Capital Assets
0.18
-86.12%
1.27
0.00
—
Restructuring And Mergern Acquisition
—
—
0.00
-100.00%
9.47
Net Income
-0.57
+73.91%
-2.18
+78.78%
-10.28
-109.18%
112.00
Pretax Income
-0.65
+72.13%
-2.34
+69.74%
-7.74
-820.86%
1.07
Net Non Operating Interest Income Expense
0.14
+5.19%
0.14
—
—
Interest Expense Non Operating
—
—
—
—
Net Interest Income
0.14
+5.19%
0.14
—
—
Interest Expense
—
—
—
—
Interest Income Non Operating
0.14
+5.19%
0.14
—
—
Interest Income
0.14
+5.19%
0.14
—
—
Other Income Expense
3.42
+44.51%
2.37
+202.94%
0.78
+108.14%
-9.59
Other Non Operating Income Expenses
3.60
-1.07%
3.63
+365.30%
0.78
+767.52%
-0.12
Tax Provision
0.00
+100.00%
-0.03
+27.91%
-0.04
0.00
Tax Rate For Calcs
0.00
-100.00%
0.00
+160.00%
0.00
0.00
Tax Effect Of Unusual Items
0.00
+100.00%
-0.02
0.00
0.00
Net Income Including Noncontrolling Interests
-0.57
+73.91%
-2.18
+78.78%
-10.28
-109.18%
112.00
Net Income From Continuing Operation Net Minority Interest
-0.65
+71.76%
-2.31
+69.97%
-7.70
-816.85%
1.07
Net Income From Continuing And Discontinued Operation
-0.57
+73.91%
-2.18
+78.78%
-10.28
-109.18%
112.00
Net Income Continuous Operations
-0.65
+71.76%
-2.31
+69.97%
-7.70
-816.85%
1.07
Net Income Discontinuous Operations
0.08
-35.88%
0.13
+105.08%
-2.58
-102.33%
110.92
Normalized Income
-0.48
+55.02%
-1.06
+86.23%
-7.70
-173.00%
10.55
Net Income Common Stockholders
-0.57
+73.91%
-2.18
+78.78%
-10.28
-109.18%
112.00
Diluted EPS
-0.05
+73.68%
-0.19
+80.61%
-0.98
-108.19%
11.96
Basic EPS
-0.05
+73.68%
-0.19
+80.61%
-0.98
-107.90%
12.41
Basic Average Shares
11.57
+0.32%
11.53
+10.45%
10.44
+15.65%
9.03
Diluted Average Shares
11.57
+0.32%
11.53
+10.45%
10.44
+11.48%
9.37
Diluted NI Availto Com Stockholders
-0.57
+73.91%
-2.18
+78.78%
-10.28
-109.18%
112.00
Depreciation Amortization Depletion Income Statement
0.38
-24.56%
0.51
-44.79%
0.92
-22.72%
1.19
Depreciation And Amortization In Income Statement
0.38
-24.56%
0.51
-44.79%
0.92
-22.72%
1.19
Total Other Finance Cost
—
—
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
37.66
-3.00%
38.82
-10.36%
43.31
-52.12%
90.46
Current Assets
14.45
+17.83%
12.26
+3.93%
11.80
-78.69%
55.35
Cash Cash Equivalents And Short Term Investments
7.48
+47.91%
5.06
+16.92%
4.33
-88.63%
38.07
Cash And Cash Equivalents
7.48
+47.91%
5.06
+16.92%
4.33
-88.63%
38.07
Cash Financial
—
—
—
38.07
Receivables
3.52
-1.04%
3.56
+15.28%
3.09
0.00
Accounts Receivable
—
—
—
—
Gross Accounts Receivable
—
—
—
—
Allowance For Doubtful Accounts Receivable
—
—
—
—
Other Receivables
3.52
-1.04%
3.56
+15.28%
3.09
—
Inventory
—
—
—
—
Raw Materials
—
—
—
—
Work In Process
—
—
—
—
Finished Goods
—
—
—
—
Prepaid Assets
—
—
0.25
-78.32%
1.17
Restricted Cash
—
—
0.00
-100.00%
11.25
Assets Held For Sale Current
—
0.00
-100.00%
0.34
0.00
Other Current Assets
3.44
-5.53%
3.64
-9.84%
4.04
-33.13%
6.03
Total Non Current Assets
23.21
-12.62%
26.56
-15.71%
31.51
-10.24%
35.11
Net PPE
5.29
-13.26%
6.10
-11.22%
6.87
-10.25%
7.66
Gross PPE
5.29
-13.26%
6.10
-11.22%
6.87
-31.97%
10.10
Accumulated Depreciation
—
—
-2.52
-3.15%
-2.44
Properties
—
—
0.00
0.00
Machinery Furniture Equipment
—
—
2.47
-0.04%
2.47
Other Properties
5.29
-13.26%
6.10
-11.22%
6.87
-9.33%
7.58
Leases
—
—
0.05
+0.00%
0.05
Goodwill And Other Intangible Assets
3.76
-12.96%
4.32
-29.14%
6.10
-12.17%
6.94
Other Intangible Assets
3.76
-12.96%
4.32
-29.14%
6.10
-12.17%
6.94
Non Current Accounts Receivable
13.71
-14.35%
16.01
-13.38%
18.48
-8.73%
20.25
Other Non Current Assets
0.44
+241.54%
0.13
+124.14%
0.06
-77.08%
0.25
Total Liabilities Net Minority Interest
10.78
-5.87%
11.45
-18.33%
14.02
-74.65%
55.31
Current Liabilities
4.79
-7.38%
5.17
-24.63%
6.85
-85.37%
46.84
Payables And Accrued Expenses
1.14
+51.99%
0.75
-55.42%
1.69
-90.93%
18.61
Payables
0.38
+46.12%
0.26
+855.56%
0.03
-98.75%
2.16
Accounts Payable
0.38
+46.12%
0.26
+855.56%
0.03
-98.75%
2.16
Current Accrued Expenses
0.77
+55.06%
0.49
-70.24%
1.66
-89.91%
16.45
Current Debt And Capital Lease Obligation
0.97
-40.29%
1.63
+10.86%
1.47
+5.97%
1.39
Current Debt
—
—
—
—
Other Current Borrowings
—
—
—
—
Current Capital Lease Obligation
0.97
-40.29%
1.63
+10.86%
1.47
+5.97%
1.39
Current Deferred Liabilities
—
—
0.00
-100.00%
1.01
Other Current Liabilities
2.67
-4.10%
2.78
-24.72%
3.69
-85.70%
25.83
Total Non Current Liabilities Net Minority Interest
6.00
-4.63%
6.29
-12.30%
7.17
-15.43%
8.48
Long Term Debt And Capital Lease Obligation
5.12
-7.58%
5.54
-15.16%
6.53
-11.36%
7.37
Long Term Capital Lease Obligation
5.12
-7.58%
5.54
-15.16%
6.53
-11.36%
7.37
Other Non Current Liabilities
0.87
+17.34%
0.74
+16.98%
0.64
-42.55%
1.11
Stockholders Equity
26.88
-1.80%
27.37
-6.55%
29.29
-16.66%
35.14
Common Stock Equity
26.88
-1.80%
27.37
-6.55%
29.29
-16.66%
35.14
Capital Stock
0.01
+0.00%
0.01
+0.00%
0.01
+22.22%
0.01
Common Stock
0.01
+0.00%
0.01
+0.00%
0.01
+22.22%
0.01
Preferred Stock
—
—
—
0.00
Share Issued
11.57
+0.36%
11.53
0.00%
11.53
+21.42%
9.50
Ordinary Shares Number
11.57
+0.36%
11.53
0.00%
11.53
+21.42%
9.50
Additional Paid In Capital
979.26
+0.01%
979.18
+0.03%
978.92
+0.45%
974.50
Retained Earnings
-952.39
-0.06%
-951.82
-0.23%
-949.64
-1.09%
-939.36
Total Equity Gross Minority Interest
26.88
-1.80%
27.37
-6.55%
29.29
-16.66%
35.14
Total Capitalization
26.88
-1.80%
27.37
-6.55%
29.29
-16.66%
35.14
Working Capital
9.66
+36.19%
7.09
+43.52%
4.94
-41.94%
8.51
Invested Capital
26.88
-1.80%
27.37
-6.55%
29.29
-16.66%
35.14
Total Debt
6.10
-15.02%
7.17
-10.37%
8.01
-8.61%
8.76
Net Debt
—
—
—
—
Capital Lease Obligations
6.10
-15.02%
7.17
-10.37%
8.01
-8.61%
8.76
Net Tangible Assets
23.11
+0.29%
23.05
-0.60%
23.19
-17.77%
28.20
Tangible Book Value
23.11
+0.29%
23.05
-0.60%
23.19
-17.77%
28.20
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
2.45
+109.74%
1.17
+105.07%
-23.08
-346.62%
9.36
Cash Flow From Continuing Operating Activities
2.45
+109.74%
1.17
+105.07%
-23.08
-346.43%
9.37
Cash From Discontinued Operating Activities
—
—
—
-13.44
Net Income From Continuing Operations
-0.65
+71.76%
-2.31
+69.97%
-7.70
-816.85%
1.07
Depreciation Amortization Depletion
1.19
-6.80%
1.28
+38.83%
0.92
-23.17%
1.20
Depreciation
1.19
-6.80%
1.28
+1180.00%
0.10
-83.33%
0.60
Amortization Cash Flow
—
—
0.80
+33.33%
0.60
Depreciation And Amortization
1.19
-6.80%
1.28
+38.83%
0.92
-23.17%
1.20
Amortization Of Intangibles
—
—
0.80
+33.33%
0.60
Other Non Cash Items
—
-0.22
-69.77%
-0.13
+67.83%
-0.40
Stock Based Compensation
0.07
-71.59%
0.26
-79.23%
1.27
-89.02%
11.57
Provisionand Write Offof Assets
—
—
—
—
Asset Impairment Charge
0.18
-86.12%
1.27
0.00
—
Change In Working Capital
1.66
+148.21%
0.67
+103.84%
-17.45
-326.97%
-4.09
Change In Receivables
—
—
—
—
Changes In Account Receivables
—
—
—
—
Change In Inventory
—
—
—
—
Change In Prepaid Assets
0.20
-49.37%
0.40
-80.14%
2.00
+222.42%
0.62
Change In Payables And Accrued Expense
0.39
+150.45%
-0.78
+95.66%
-17.85
-684.99%
3.05
Change In Accrued Expense
0.27
+127.04%
-1.01
+93.60%
-15.71
-468.68%
4.26
Change In Payable
0.12
-48.48%
0.23
+110.82%
-2.13
-76.30%
-1.21
Change In Account Payable
0.12
-48.48%
0.23
+110.82%
-2.13
-76.30%
-1.21
Change In Other Current Assets
2.02
+4.66%
1.93
+271.40%
-1.13
+85.25%
-7.64
Change In Other Current Liabilities
-0.95
-7.60%
-0.88
-87.26%
-0.47
-289.26%
-0.12
Investing Cash Flow
—
—
0.00
+100.00%
-0.35
Cash Flow From Continuing Investing Activities
—
—
0.00
+100.00%
-0.35
Cash From Discontinued Investing Activities
—
—
—
223.83
Net PPE Purchase And Sale
—
—
—
0.00
Purchase Of PPE
—
—
—
0.00
Capital Expenditure
—
—
—
-0.35
Net Intangibles Purchase And Sale
—
—
0.00
+100.00%
-0.35
Purchase Of Intangibles
—
—
—
-0.35
Financing Cash Flow
—
0.00
-100.00%
3.15
+101.34%
-235.21
Cash Flow From Continuing Financing Activities
—
0.00
-100.00%
3.15
+101.34%
-235.21
Net Issuance Payments Of Debt
—
—
0.00
+100.00%
-219.43
Issuance Of Debt
—
—
—
—
Repayment Of Debt
—
—
0.00
+100.00%
-219.43
Long Term Debt Issuance
—
—
—
—
Long Term Debt Payments
—
—
0.00
+100.00%
-219.43
Net Long Term Debt Issuance
—
—
0.00
+100.00%
-219.43
Short Term Debt Payments
—
—
—
-219.43
Net Short Term Debt Issuance
—
—
—
-219.43
Net Common Stock Issuance
—
0.00
-100.00%
3.15
+27.67%
2.47
Repurchase Of Capital Stock
—
—
0.00
+100.00%
-38.66
Proceeds From Stock Option Exercised
—
—
—
0.00
Net Other Financing Charges
—
—
—
-1.27
Changes In Cash
2.42
+231.15%
0.73
+101.63%
-44.99
-184.66%
-15.80
Beginning Cash Position
5.06
+16.92%
4.33
-91.23%
49.32
-24.27%
65.12
End Cash Position
7.48
+47.91%
5.06
+16.92%
4.33
-91.23%
49.32
Free Cash Flow
2.45
+109.74%
1.17
+105.07%
-23.08
-356.34%
9.00
Interest Paid Supplemental Data
—
—
0.00
-100.00%
13.54
Common Stock Issuance
—
0.00
-100.00%
3.15
+27.67%
2.47
Issuance Of Capital Stock
—
0.00
-100.00%
3.15
-86.95%
24.15
Net Preferred Stock Issuance
—
—
0.00
+100.00%
-16.97
Preferred Stock Issuance
—
—
0.00
-100.00%
21.68
Preferred Stock Payments
—
—
0.00
+100.00%
-38.66
Cash Flow From Discontinued Operation
-0.03
+93.15%
-0.44
+98.25%
-25.06
-111.91%
210.40
Cash From Discontinued Financing Activities
—
—
—
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category